Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics.
Authors
Lallo, AliceGulati, Sakshi
Schenk, Maximilian W
Khandelwal, Garima
Berglund, UW
Pateras, IS
Chester, Christopher P E
Pham, TM
Kalderen, C
Frese, Kristopher K
Gorgoulis, Vassilis G
Miller, Crispin J
Blackhall, Fiona H
Helleday, T
Dive, Caroline
Affiliation
Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Macclesfield, SK10 4TG, UKIssue Date
2018
Metadata
Show full item recordAbstract
BACKGROUND AND PURPOSE: Small cell lung cancer (SCLC) is an aggressive disease with median survival of < 2 years. Tumour biopsies for research are scarce, especially from extensive-stage patients, with repeat sampling at disease progression rarely performed. We overcame this limitation for relevant preclinical models by developing SCLC circulating tumour cell derived explants (CDX) which mimic the donor tumour pathology and chemotherapy response. To facilitate compound screening and identification of clinically relevant biomarkers, we developed short term ex vivo cultures of CDX tumour cells.Citation
Lallo A, Gulati S, Schenk M, Khandelwal G, Berglund U, Pateras I, et al. Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics. Br J Pharmacol. 2018 Nov 14.Journal
British Journal of PharmacologyDOI
10.1111/bph.14542PubMed ID
30427531Additional Links
https://dx.doi.org/10.1111/bph.14542Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bph.14542
Scopus Count
Collections
Related articles
- Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.
- Authors: Morrow CJ, Trapani F, Metcalf RL, Bertolini G, Hodgkinson CL, Khandelwal G, Kelly P, Galvin M, Carter L, Simpson KL, Williamson S, Wirth C, Simms N, Frankliln L, Frese KK, Rothwell DG, Nonaka D, Miller CJ, Brady G, Blackhall FH, Dive C
- Issue date: 2016 Jun
- Cisplatin and photodynamic therapy exert synergistic inhibitory effects on small-cell lung cancer cell viability and xenograft tumor growth.
- Authors: Cheng YS, Peng YB, Yao M, Teng JP, Ni D, Zhu ZJ, Zhuang BF, Yang ZY
- Issue date: 2017 Jun 3
- The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
- Authors: Lallo A, Frese KK, Morrow CJ, Sloane R, Gulati S, Schenk MW, Trapani F, Simms N, Galvin M, Brown S, Hodgkinson CL, Priest L, Hughes A, Lai Z, Cadogan E, Khandelwal G, Simpson KL, Miller C, Blackhall F, O'Connor MJ, Dive C
- Issue date: 2018 Oct 15
- Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
- Authors: Morimura O, Minami T, Kijima T, Koyama S, Otsuka T, Kinehara Y, Osa A, Higashiguchi M, Miyake K, Nagatomo I, Hirata H, Iwahori K, Takimoto T, Takeda Y, Kida H, Kumanogoh A
- Issue date: 2017 Jul 8
- Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants.
- Authors: Vickers AJ, Frese K, Galvin M, Carter M, Franklin L, Morris K, Pierce J, Descamps T, Blackhall F, Dive C, Carter L
- Issue date: 2020 Dec